Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381103 | 0.82 | EGFR (0.52) | MAPK1TSHRALOX15TP53SMN1; SMN2 | |
| SCHEMBL12297373 | 0.80 | KDM4E (0.52) | MAPK1TSHRALOX15TP53SMN1; SMN2 | |
| SCHEMBL20966396 | 0.75 | TSHR (0.53) | MAPK1TSHRALOX15TP53SMN1; SMN2 | |
| SCHEMBL2381779 | 0.73 | GLA (0.49) | TSHRTP53SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL12245702 | 0.73 | MAPK14 (0.42) | MAPK1TSHRALOX15TP53SMN1; SMN2 | |
| SCHEMBL31565201 | 0.73 | MAPT (0.56) | MAPK1TSHRALOX15TP53MAPT | |
| SCHEMBL1257160 | 0.72 | KDR (0.50) | NPSR1LMNAKDM4EKMT2APOLB | |
| SCHEMBL3234489 | 0.71 | NPC1 (0.51) | MAPK1TSHRALOX15SMN1; SMN2MAPT | |
| SCHEMBL3971420 | 0.70 | IRAK4 (0.58) | MAPK1TSHRALOX15TP53SMN1; SMN2 | |
| SCHEMBL4272871 | 0.69 | HRH4 (0.54) | TSHRALOX15MAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008086014-A2 | BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | MET, REL, NAT1 | MAPK1 2606/4885TSHR 1900/4885ALOX15 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.